As per reports, UnitedHealth Group Incorporated (UNH) topped market estimates reporting a rise of 25.4% in its adjusted earnings versus a year earlier to $5.34 per share, and 17 cents ahead of estimates. Revenue grew 12.3% to $82.79 billion, edging past estimates of $82.59 billion. The medical cost ratio paid benefits as a share of premiums dropped to 82.8% vs. 83.7% in the year-ago quarter, and medical membership grew by 375,000 from the prior quarter.
The Dow 30 component added 130,000 commercial members, 70,000 Medicare Advantage members, and 165,000 Medicaid members. Optum Health’s revenue per consumer served rose by 29% in 2022. The company reiterated full-year 2023 earnings guidance of $24.40 to $24.90 per share and cash flow from operations of $27 billion to $28 billion.
Dow 30 component UnitedHealth Group Incorporated (UNH) operates as a diversified health and well-being company in the United States. The company’s UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, individuals, and military service members; and health care coverage, and health and well-being services to individuals aged 50 and older addressing their needs for preventive and acute health care services. To learn more about (UNH) please visit the Vista Partners Company Dedicated UNH Coverage Page.
Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.
DID YOU KNOW?
Fertility rates have hit a record low in the United States. The latest US government fertility statistics come from 2019, and they estimate there were 58.2 births year per 1,000 women of childbearing age (defined by the CDC as women between ages 15 and 44).
If you have ever struggled with infertility issues, or know someone who has, you are probably well aware of how demoralizing it can be. Imagine for a moment spending thousands of dollars and months of intensive medical procedure only to end up empty handed, exhausted, sad, and defeated because after all of that time, work, and money, you still don’t have a baby. That’s an incredibly difficult situation, and it’s becoming more common each passing year. Likewise, the need for more effective, less invasive infertility treatment options is increasing with each passing year. This is the sole focus of medtech company INVO Bioscience (NASDAQ: INVO). Learn more by reading the following story that we published recently.
